Information Provided By:
Fly News Breaks for August 5, 2019
ETON
Aug 5, 2019 | 09:21 EDT
Lake Street analyst Brooks O'Neil started Eton Pharmaceuticals with a Buy rating and $15 price target. The company has a "diversified" pipeline of 12 product candidates in various stages of development which are targeting a number of therapeutic areas, O'Neil tells investors in a research note. The analyst sees the potential for $69M of revenue from the first three of the 12 products in its pipeline. Further, he believes Eton's management team has a track record of successfully growing businesses through "value-creating business development activities."
News For ETON From the Last 2 Days
There are no results for your query ETON